In a recent update from Marseille, France, Innate Pharma shared updated efficacy and safety results from the Phase 1/2 study with SAR443579/IPH6101, an NK cell engager targeting CD123 developed in collaboration with Sanofi.
What is SAR443579/IPH6101 and what is its potential impact on patients with blood cancers?
SAR443579/IPH6101 is a first-in-class NKp46/CD16-based NK cell engager targeting CD123, currently being developed by Sanofi for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) and high-risk myelodysplasia (HR-MDS). The drug has shown promising clinical benefit and durable responses in patients with R/R AML, with 5 complete remissions achieved at a dose of 1 mg/kg, including 4 CR and 1 CRi.
What are the key highlights from the Phase 1/2 study presented at the European Hematology Association 2024 Congress?
In the study led by Sanofi, 59 patients across 11 dose levels were treated with SAR443579/IPH6101. The maximum response rate was observed at a dose of 1 mg/kg, with 5 AML patients achieving complete remissions. Three patients showed durable complete remission for over 10 months, and the drug was well tolerated up to doses of 6 mg/kg. These results mark a significant milestone in the development of SAR443579/IPH6101 and pave the way for further studies in the Phase 2 portion of the trial.
What is ANKET® platform, and how does it contribute to the development of SAR443579/IPH6101?
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific natural killer cell engagers to treat certain types of cancer. This innovative technology is creating a new class of molecules to induce synthetic immunity against cancer, with SAR443579/IPH6101 being a lead asset developed through this platform.
What are the future plans for the development of SAR443579/IPH6101?
Ongoing studies are focused on further demonstrating the potential of SAR443579/IPH6101 in patients with leukemia. Sanofi, in collaboration with Innate Pharma, is committed to advancing the development of this NK cell engager and looks forward to sharing more data from upcoming trials at scientific meetings.
In conclusion, the progress of SAR443579/IPH6101 in the treatment of blood cancers marks a significant advancement in the field of immuno-oncology. With promising clinical results and a favorable safety profile, this NK cell engager holds great potential to benefit patients suffering from various types of leukemia. Stay tuned for more updates on the development of SAR443579/IPH6101 as it continues to show promise in the fight against cancer.
